Conclusion
diabetic
CVD, INSULIN RESISTANCE, INSULIN SENSITIVITY, CARDIOVASCULAR DISEASES
Both glimepiride or dapagliflozin significantly improved glycemic control, insulin resistance (as indicated by HOMA-IR), and NT-proBNP with no significant difference between them in type 2 diabetic patients. However, dapagliflozin has a borderline significant effect on IRAPe, and did not affect IL-34 significantly, while glimepiride has a significant effect on IL-34 but not IRAPe.Since both drugs have improved the levels of NT-proBNP they can be recommended for diabetic patients who are at high risk for developing cardiovascular diseases (CVD). Both drugs have improved insulin sensitivity so they can be very useful for patients with high insulin resistance, with glimepiride more recommended for patients with high level of IL-34. Although, larger scale studies with longer follow-up duration are still needed to determine the benefits of both medications in diabetic patients.